Exocrine Pancreatic Insufficiency Market Size & Growth Forecast 2026–2035, By Segments (Therapy, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Exocrine Pancreatic Insufficiency Market size was more than USD 3.57 Billion in 2025 and is set to grow at a 6.7% CAGR between 2026 and 2035, attaining USD 6.83 Billion by 2035. The industry revenue for 2026 is estimated at USD 3.77 billion.

• Base Year Value (2025): USD 3.57 Billion
• CAGR (2026-2035): 6.7%
• Forecast Year Value (2035): USD 6.83 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Exocrine Pancreatic Insufficiency Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads through established diagnosis pathways, strong physician awareness, specialist care access, and structured follow-up that supports consistent pancreatic enzyme replacement therapy use.
  • Asia Pacific is expected to expand at a 7.57% CAGR as improving diagnostics, broader gastroenterology access, and formalized treatment pathways bring more previously underdiagnosed patients into care.

• Segment Momentum:

  • Pancreatic Enzyme Replacement Therapy is the largest and fastest-growing segment because it directly addresses digestive enzyme deficiency and supports long-term symptom control through consistent therapy use.
  • Retail Pharmacies are growing fastest by providing convenient refill access for patients receiving long-term enzyme replacement therapy, supporting routine outpatient treatment continuation beyond hospital care.

• Market Expansion Drivers:

  • Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics.
  • Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases.
  • Advancements in diagnostic technologies improving early detection and long-term management of EPI patients.

• Leading Market Participants:

  Prominent companies in the exocrine pancreatic insufficiency market include AbbVie Inc. (United States), AstraZeneca PLC (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (United States), Bayer AG (Germany), Janssen Pharmaceuticals NV (Belgium), Abbott Laboratories (United States), Sun Pharmaceutical Industries Limited (India), Cipla Limited (India), Nestlé Health Science S.A. (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 3.57 Billion
  • Projected Market Size: USD 6.83 Billion by 2035
  • Growth Forecasts: 6.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Pancreatic Enzyme Replacement Therapy (Therapy) | Hospital Pharmacy (Distribution Channel)
  • Emerging Opportunity Segment: Pancreatic Enzyme Replacement Therapy (Therapy) | Retail Pharmacy (Distribution Channel)

Market Growth Drivers and Industry Trends

Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics

As chronic pancreatitis becomes more prevalent, a larger share of patients progresses to impaired pancreatic enzyme secretion, creating a steady flow of clinically confirmed and suspected cases that require evaluation and ongoing care. In the exocrine pancreatic insufficiency market, this translates directly into higher utilization of pancreatic enzyme replacement therapies as symptom control often depends on long-term dosing tailored to meal patterns, nutritional status, and disease severity. The same patient pathway also reinforces demand for diagnostics, since persistent malabsorption, weight loss, and gastrointestinal symptoms in chronic pancreatitis patients push clinicians to distinguish exocrine insufficiency from overlapping digestive disorders and to monitor treatment response over time.

Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases

The expanding diabetes population is increasing clinical attention on pancreatic dysfunction beyond glycemic control, especially as physicians encounter patients with unexplained gastrointestinal symptoms, poor nutrient absorption, or unstable metabolic control that may indicate underlying exocrine impairment. This is encouraging market growth in the exocrine pancreatic insufficiency market by widening the screened and treated patient pool, particularly in endocrinology and multi-specialty care settings where links between diabetes and pancreatic insufficiency are becoming more actively recognized. As a result, diagnosis is occurring in patients who might previously have remained untreated, and that shift is driving demand for both confirmatory testing and enzyme replacement therapy integrated into broader chronic disease management.

Advancements in diagnostic technologies improving early detection and long-term management of EPI patients

Improved diagnostic tools are changing how exocrine pancreatic insufficiency is identified, reducing reliance on late-stage clinical suspicion and enabling clinicians to detect functional pancreatic decline earlier in patients with nonspecific digestive complaints or underlying pancreatic disease. In the exocrine pancreatic insufficiency market, this strengthens market development by moving more patients into treatment pathways before severe malnutrition or weight loss emerges, which supports earlier initiation of enzyme replacement therapy and more consistent follow-up. Better testing also helps physicians adjust therapy over time with greater confidence, making long-term management more structured and increasing the likelihood that diagnosed patients remain on sustained treatment rather than cycling through empiric gastrointestinal therapies.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising chronic pancreatitis incidence increasing demand for enzyme replacement therapies and diagnostics	1.90%	High	North America, Europe, Asia Pacific	High	Near Term
Growing diabetes prevalence strengthening identification and treatment of associated pancreatic insufficiency cases	1.70%	Moderate	Asia Pacific, North America	Medium	Mid Term
Advancements in diagnostic technologies improving early detection and long-term management of EPI patients	1.40%	High	Europe, North America	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional share of the exocrine pancreatic insufficiency market in 2025, supported by established diagnosis pathways, broad physician awareness of pancreatic enzyme replacement therapy, and routine access to specialist care for gastrointestinal and pancreatic disorders. The region’s leadership is aided by healthcare systems that are better positioned to identify symptomatic patients earlier, particularly where chronic pancreatitis, cystic fibrosis, and post-surgical digestive complications are actively managed through structured clinical follow-up. This supports steadier prescription volumes and treatment continuity in everyday practice, rather than leaving patient identification dependent on late-stage presentation.

Asia Pacific is projected to expand at a 7.57% CAGR over the forecast period, with growth in the exocrine pancreatic insufficiency market being propelled by improving recognition of digestive enzyme disorders and wider access to gastroenterology care across developing healthcare systems. As diagnostic capabilities become more available and treatment pathways become more formalized, a larger pool of previously underdiagnosed patients is moving into managed care. Growth is further supported by rising clinical attention to pancreatic and malabsorption-related conditions, which is translating into more consistent therapy uptake across both hospital and outpatient settings.

Key Country Insights

United States

Advanced Diagnostic Adoption

The U.S. emphasizes earlier diagnosis of exocrine pancreatic insufficiency through specialist gastroenterology networks and improved clinical awareness. Growing use of pancreatic enzyme replacement therapy is supported by patient education initiatives and integrated management of chronic pancreatic disorders.

Japan

Aging Patient Focus

Japan addresses exocrine pancreatic insufficiency with attention to its aging population and increasing prevalence of chronic pancreatic diseases. Healthcare providers focus on nutritional optimization and personalized enzyme replacement strategies to improve patient quality of life.

South Korea

Specialist Treatment Expansion

South Korea is strengthening specialist-led diagnosis and treatment of exocrine pancreatic insufficiency within advanced healthcare facilities. Greater clinical awareness and improved access to pancreatic enzyme therapies support more comprehensive disease management.

Germany

Guideline-Based Care

Germany prioritizes standardized diagnostic pathways and evidence-based treatment protocols for exocrine pancreatic insufficiency. Collaboration between hospitals and outpatient specialists encourages consistent use of enzyme replacement therapy and long-term nutritional management.

France

Nutritional Care Integration

France integrates nutritional assessment with pharmacological management for patients with exocrine pancreatic insufficiency. Multidisciplinary care models encourage coordinated treatment approaches that improve digestive health and patient adherence.

Italy

Clinical Management Refinement

Italy focuses on improving recognition of exocrine pancreatic insufficiency among patients with chronic gastrointestinal and pancreatic disorders. Greater emphasis on optimized enzyme dosing and follow-up supports more consistent therapeutic outcomes.

Segment Leadership and Growth Trends

  Therapy Segment Analysis: Pancreatic Enzyme Replacement Therapy (Largest & Fastest-Growing Segment)

Within the exocrine pancreatic insufficiency market, Pancreatic Enzyme Replacement Therapy held the largest share in 2025 and continues to post the fastest growth because it directly addresses the core digestive enzyme deficiency that defines the condition. its position is maintained through its central role in routine disease management, where symptom control and nutritional support depend on ongoing enzyme supplementation rather than intermittent treatment. The same treatment relevance is also driving continued expansion in the exocrine pancreatic insufficiency market, as demand rises for therapies that can be integrated into long-term care pathways and used consistently across patients with persistent pancreatic function impairment.

Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)

Hospital Pharmacy accounted for the largest share of the exocrine pancreatic insufficiency market in 2025, aided by the clinical nature of diagnosis and treatment initiation for pancreatic disorders. Patients with exocrine pancreatic insufficiency are often identified and managed in hospital-based settings, where specialist oversight, prescription management, and coordination with broader gastrointestinal or pancreatic care make hospital pharmacies the leading dispensing channel. This established connection between diagnosis, treatment planning, and hospital-based access continues to sustain its share in the market.

Retail Pharmacy is emerging as the fastest-growing distribution channel in the exocrine pancreatic insufficiency market because ongoing therapy use increasingly aligns with convenient refill access outside acute care settings. As patients remain on long-term pancreatic enzyme therapy, retail pharmacies are well positioned to support repeat dispensing and routine treatment continuation closer to home. That practical advantage is helping retail pharmacy grow faster than hospital-based channels, particularly where treatment shifts from initial specialist management to regular outpatient maintenance.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Therapy	Pancreatic Enzyme Replacement Therapy, Natural Therapy	Pancreatic Enzyme Replacement Therapy	Pancreatic Enzyme Replacement Therapy
Distribution Channel	Hospital Pharmacy, Retail Pharmacy, Others	Hospital Pharmacy	Retail Pharmacy

Competitive Landscape and Market Positioning

Prominent players in the exocrine pancreatic insufficiency market:

1. AbbVie Inc. (United States)

2. AstraZeneca PLC (United Kingdom)

3. Takeda Pharmaceutical Company Limited (Japan)

4. Pfizer Inc. (United States)

5. Bayer AG (Germany)

6. Janssen Pharmaceuticals NV (Belgium)

7. Abbott Laboratories (United States)

8. Sun Pharmaceutical Industries Limited (India)

9. Cipla Limited (India)

10. Nestlé Health Science S.A. (Switzerland)

The exocrine pancreatic insufficiency market is progressing through improved enzyme replacement innovations and formulation optimization. Research-driven initiatives are enhancing treatment efficiency and digestive absorption outcomes. New therapeutic options are being introduced to address varied patient needs and severity levels. Technology integration in drug formulation is also supporting improved stability and delivery performance.

Industry Development/News

Company Name	Date	Key Development
Anagram Therapeutics	May-26	Anagram Therapeutics secured a USD 250 million investment from Blackstone Life Sciences to advance ANG003, a novel oral recombinant enzyme replacement therapy. The funding supports clinical development, regulatory approval, and commercialization efforts targeting exocrine pancreatic insufficiency across cystic fibrosis, pancreatic cancer, and related conditions.
Blackstone Life Sciences	May-26	Blackstone Life Sciences committed USD 250 million to Anagram Therapeutics to support development and commercialization of next-generation oral enzyme replacement therapies. The investment strengthens pipeline advancement in exocrine pancreatic insufficiency treatment and supports future market entry of novel therapeutic solutions.
Nestlé S.A.	Jan-20	Nestlé S.A. entered an asset purchase agreement with Allergan to acquire the gastrointestinal drug Zenpep. The acquisition strengthened Nestlé’s medical nutrition portfolio and expanded its presence in enzyme-based therapies used in digestive disorders including exocrine pancreatic insufficiency.
Alcresta Therapeutics	Apr-25	Alcresta Therapeutics enrolled the first patient in an investigator-initiated clinical trial at Massachusetts General Hospital evaluating RELiZORB for exocrine pancreatic insufficiency in tube-fed pancreatitis patients. The study supports clinical validation of enzyme-based nutritional support solutions for severe pancreatic dysfunction.
Horizon Therapeutics	Apr-25	Horizon Therapeutics received FDA approval for Uplizna (inebilizumab-cdon) for IgG4-related disease, a condition linked to autoimmune pancreatitis. The approval introduces a targeted immune therapy approach relevant to pancreatic disease management and supports expansion of treatment options in immune-mediated pancreatic disorders.
Adalvo	Mar-25	Adalvo prepared for the European launch of pancreatin delayed-release capsules, a key enzyme replacement therapy for exocrine pancreatic insufficiency. The initiative aims to expand access to enzyme-based treatments and strengthen its position in the gastrointestinal therapeutics market across Europe.
AbbVie	2025	AbbVie presented updated gastrointestinal research data, with continued support for studies in digestive disorders including exocrine pancreatic insufficiency. The activity reflects ongoing engagement in advancing therapeutic understanding across broader gastrointestinal disease areas relevant to enzyme deficiency conditions.